JP2010514455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514455A5 JP2010514455A5 JP2009544412A JP2009544412A JP2010514455A5 JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5 JP 2009544412 A JP2009544412 A JP 2009544412A JP 2009544412 A JP2009544412 A JP 2009544412A JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- composition
- antigen
- composition according
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 210000004698 lymphocyte Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000035131 DNA demethylation Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 230000006195 histone acetylation Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000003698 anagen phase Effects 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000006197 histone deacetylation Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700058.1 | 2007-01-03 | ||
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514455A JP2010514455A (ja) | 2010-05-06 |
| JP2010514455A5 true JP2010514455A5 (enExample) | 2012-10-25 |
| JP5452231B2 JP5452231B2 (ja) | 2014-03-26 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544412A Expired - Fee Related JP5452231B2 (ja) | 2007-01-03 | 2008-01-03 | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (enExample) |
| EP (1) | EP2102331B1 (enExample) |
| JP (1) | JP5452231B2 (enExample) |
| AT (1) | ATE522600T1 (enExample) |
| AU (1) | AU2008203730B2 (enExample) |
| CY (1) | CY1112668T1 (enExample) |
| DK (1) | DK2102331T3 (enExample) |
| ES (1) | ES2372713T3 (enExample) |
| GB (1) | GB0700058D0 (enExample) |
| HR (1) | HRP20110899T1 (enExample) |
| PL (1) | PL2102331T3 (enExample) |
| PT (1) | PT2102331E (enExample) |
| SI (1) | SI2102331T1 (enExample) |
| WO (1) | WO2008081035A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8467973B2 (en) | 2009-07-28 | 2013-06-18 | Promising Future, Llc | Pairing processes for preparing alloreactive cytotoxic T cells |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| US9211321B2 (en) | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| KR20230005428A (ko) | 2015-05-28 | 2023-01-09 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 진단 방법 |
| IL292504B2 (en) | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| SG10201912519VA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| EP3583129B1 (en) | 2017-02-14 | 2021-11-03 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| KR20190130024A (ko) | 2017-04-03 | 2019-11-20 | 카이트 파마 인코포레이티드 | 최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료 |
| BR102018008260A2 (pt) | 2017-04-24 | 2020-04-28 | Kite Pharma, Inc. | domínios de ligação ao antígeno humanizado e métodos de uso |
| US12097218B2 (en) | 2017-05-26 | 2024-09-24 | Kite Pharma, Inc. | Methods of making and using embryonic mesenchymal progenitor cells |
| CN111315403A (zh) | 2017-09-15 | 2020-06-19 | 凯德药业股份有限公司 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| EP3697500A1 (en) | 2017-10-18 | 2020-08-26 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| AU2019206724A1 (en) | 2018-01-15 | 2020-07-16 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist |
| WO2019152957A1 (en) | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| CA3090793C (en) | 2018-02-16 | 2024-10-08 | Kite Pharma, Inc. | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE |
| CN119656304A (zh) | 2018-04-12 | 2025-03-21 | 凯德药业股份有限公司 | 使用肿瘤微环境的特征的嵌合受体t细胞治疗 |
| KR102734592B1 (ko) | 2018-06-01 | 2024-11-27 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| US20210155941A1 (en) | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| AU2019314452B2 (en) | 2018-08-02 | 2022-12-08 | Kite Pharma, Inc | Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| WO2020208054A1 (en) | 2019-04-12 | 2020-10-15 | Cytovac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| CN114206346A (zh) | 2019-05-03 | 2022-03-18 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| CN114391021B (zh) | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| WO2021046134A1 (en) | 2019-09-03 | 2021-03-11 | Allogene Therapeutics, Inc. | Methods of preparing t cells for t cell therapy |
| IL292665B2 (en) | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| WO2021168375A1 (en) | 2020-02-20 | 2021-08-26 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| EP4501951A3 (en) | 2020-08-25 | 2025-04-30 | Kite Pharma, Inc. | T cells with improved functionality |
| AU2021369507B2 (en) | 2020-10-28 | 2025-06-26 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| WO2022140159A1 (en) | 2020-12-24 | 2022-06-30 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
| WO2022150582A1 (en) | 2021-01-10 | 2022-07-14 | Kite Pharma, Inc. | T cell therapy |
| EP4281545A1 (en) | 2021-01-21 | 2023-11-29 | CytoVac A/S | Method for t-cell expansion and related medical applications |
| JP2024507199A (ja) | 2021-02-20 | 2024-02-16 | カイト ファーマ インコーポレイテッド | 免疫療法を選択するための遺伝子マーカー |
| KR20230155521A (ko) | 2021-03-11 | 2023-11-10 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| US12337035B2 (en) | 2021-04-16 | 2025-06-24 | Kite Pharma, Inc. | TACI binding molecules |
| EP4323943A1 (en) | 2021-04-16 | 2024-02-21 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| KR20230173179A (ko) | 2021-05-14 | 2023-12-26 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t세포 요법 |
| AU2022282266B2 (en) | 2021-05-24 | 2025-09-18 | Kite Pharma, Inc. | NKG2D-based chimeric antigen receptor |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| US20230103457A1 (en) | 2021-07-02 | 2023-04-06 | Kite Pharma, Inc. | Method for identifying variants in gene products from gene constructs used in cell therapy applications |
| US20230060292A1 (en) | 2021-07-26 | 2023-03-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| KR20240027077A (ko) | 2021-07-30 | 2024-02-29 | 카이트 파마 인코포레이티드 | 세포 요법-유도 독성의 모니터링 및 관리 |
| US20230303655A1 (en) | 2021-10-18 | 2023-09-28 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
| CN118742810A (zh) | 2022-02-15 | 2024-10-01 | 凯德药业股份有限公司 | 从免疫疗法预测不良事件 |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| JP2026508791A (ja) | 2022-10-28 | 2026-03-13 | カイト ファーマ インコーポレイテッド | 免疫療法の有効性及び永続的奏効の改善 |
| TWI882495B (zh) | 2022-10-28 | 2025-05-01 | 美商凱特製藥公司 | 用於將免疫療法最佳化之因素 |
| CN120917153A (zh) | 2023-03-17 | 2025-11-07 | 凯德药业股份有限公司 | 肿瘤微环境对免疫疗法疗效的影响 |
| US20250161361A1 (en) | 2023-11-01 | 2025-05-22 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| US20250262300A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| US20250290154A1 (en) | 2024-03-04 | 2025-09-18 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| TW202604957A (zh) | 2024-05-03 | 2026-02-01 | 美商凱特製藥公司 | 嵌合受體及其使用方法 |
| US20250382383A1 (en) | 2024-05-31 | 2025-12-18 | Kite Pharma, Inc. | Tricistronic constructs for anti-gpc3 car |
| TW202607133A (zh) | 2024-07-08 | 2026-02-16 | 美商凱特製藥公司 | 用於對活細胞施加機械力以產生表型反應的系統及方法 |
| WO2026084968A1 (en) | 2024-10-14 | 2026-04-23 | Kite Pharma, Inc. | Biomarker based standards and methods of use |
| US20260224626A1 (en) | 2024-11-04 | 2026-08-06 | Kite Pharma, Inc. | Biomarkers related to immunotherapy efficacy |
| WO2026136591A1 (en) | 2024-12-18 | 2026-06-25 | Kite Pharma, Inc. | Jaml transmembrane and co-signaling domains for chimeric antigen receptors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en not_active Ceased
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110899T1 (hr) | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ | |
| JP6134763B2 (ja) | ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
| AU2003203051B2 (en) | Cancer therapy | |
| JP2015512866A5 (enExample) | ||
| JP2013535218A5 (enExample) | ||
| Pizzurro et al. | Dendritic cell-based vaccine efficacy: aiming for hot spots | |
| Schneiders et al. | Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection | |
| Taniguchi et al. | Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy | |
| JP2013177430A5 (enExample) | ||
| Ning et al. | β‐glucan restores tumor‐educated dendritic cell maturation to enhance antitumor immune responses | |
| JP2014514927A5 (enExample) | ||
| Kobayashi et al. | Fever-range whole-body heat treatment stimulates antigen-specific T-cell responses in humans | |
| Huarte et al. | Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma | |
| Shui et al. | β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells | |
| Choi et al. | The function of memory CD8+ T cells in immunotherapy for human diseases | |
| JP2014533938A5 (enExample) | ||
| CN109762788A (zh) | 一种car-t细胞的制备方法 | |
| Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
| Lichtenegger et al. | Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade | |
| Liseth et al. | Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience | |
| Gritzapis et al. | Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice | |
| Xu et al. | Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
| Peng et al. | EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model | |
| Iwabuchi et al. | Against Lung Cancer and Head and |